BioAtla Investor Presentation Deck

Phase 2 study design with BA3021 (Ozuriftamab Vedotin) in refractory patients for each indication: NSCLC, Melanoma, and SCCHN Initial interim analysis ROR2+ ≥1 TmPS ● ● Melanoma*: PD1 failure NSCLC: PD1, EGFR or ALK failure SCCHN: PD1 alone or in combination w/ platinum failure Monotherapy and Combination with PD-1/L1 Targeting up to ~20 pts *To date, CR on first scan (3 doses), n=1 Next step If definitive, move into part 2 Ability to continue enrollment up to ~40 patients, if desired Phase 2 part 2 Monotherapy (BA3021) and / or Combination (BA3021+Opdivo) n=TBD pending discussions with FDA BA3011 dose 1.8 mg/kg Q2W. Inclusion criteria: measurable disease, ≥ 18 years, ECOG performance status 0 or 1. bicatla AE, adverse event, BOR, best overall response; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SAE, serious adverse event; TTR, time to response. Endpoints Primary endpoints ● ● Confirmed ORR per RECIST v1.1 AES or SAEs Secondary endpoints ● DOR, PFS, ORR, DCR, TTR, OS, tumor size BioAtla| Overview 28

View entire presentation